Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
(terazosin hydrochloride)
909 results
  • LiverTox: Clinical and Research Information on Drug-Induced Liver Injury: Alpha 1 Adrenergic Receptor Antagonists [BOOK]
    National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda (MD)BOOK
  • The alpha-1 adrenergic receptor antagonists (also called alpha-blockers) are a family of agents that bind to and inhibit type 1 alpha-adrenergic receptors and thus inhibit smooth muscle contraction. Their major uses are for hypertension and for symptomatic benign prostatic hypertrophy. Their use in therapy of hypertension is based on the inhibition of vascular resistance in arterioles from alpha-…
  • LiverTox: Clinical and Research Information on Drug-Induced Liver Injury: Terazosin [BOOK]
    National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda (MD)BOOK
  • Terazosin is a nonselective alpha-1 adrenergic antagonist used in the therapy of hypertension and benign prostatic hypertrophy. Terazosin therapy is associated with a low rate of transient serum aminotransferase elevations and to rare instances of clinically apparent acute liver injury.
  • Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases. [Journal Article]
    J Clin Invest 2019; 129(10):4539-4549Cai R, Zhang Y, … Liu L
  • Parkinson's disease (PD) is a common neurodegenerative disease that lacks therapies to prevent progressive neurodegeneration. Impaired energy metabolism and reduced ATP levels are common features of PD. Previous studies revealed that terazosin (TZ) enhances the activity of phosphoglycerate kinase 1 (PGK1), thereby stimulating glycolysis and increasing cellular ATP levels. Therefore, we asked whet…
  • Terazosin or baclofen in young men with chronic orchialgia: A cohort study of 499 patients. [Journal Article]
    Urologia 2019; :391560319873531Mohseni-Rad H, Razzaghdoust A, … Hosseinkhani A
  • CONCLUSIONS: Although a significant reduction was observed in mean National Institutes of Health Chronic Prostatitis Symptom Index score for both terazosin and baclofen groups, there was no significant difference between the treatments. Moreover, addition of varicocelectomy to terazosin or baclofen could not significantly decrease National Institutes of Health Chronic Prostatitis Symptom Index score; thus, varicocelectomy may not be appropriate for men who have some success with medical management. Further randomized studies are warranted.
  • StatPearls: Terazosin [BOOK]
    StatPearls Publishing: Treasure Island (FL) Yang Cheng H. CH USHEC - San Antonio Raja Avais A BOOK
  • Terazosin was approved by the Food and Drug Administration (FDA) in 1987 initially as a treatment for hypertension and then approved in 1993 as a treatment for lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia.[1][2] In more recent literature, terazosin, among other agents of its class been the subject of research as an off-label agent for the use of medical expulsi…
  • Anticholinergic and sedative medications exposure in older patients: a cross-sectional study. [Journal Article]
    Int J Clin Pharm 2019; 41(5):1152-1158Zhang X, Zhou S, … Liu X
  • Background The Drug Burden Index is a risk assessment tool used to quantify anticholinergic and sedative medications burden of older patients. There have been no previously published reports the exposure of anticholinergic and sedative medications in China. Objective We investigated the prevalence and correlates risk factors of anticholinergic and sedative medications in hospitalized older patien…
  • Revisiting the Pharmacodynamic Uroselectivity of α 1-Adrenergic Receptor Antagonists. [Journal Article]
    J Pharmacol Exp Ther 2019; 371(1):106-112Quaresma BMCS, Pimenta AR, … Noël F
  • α1-Adrenoceptor (AR) antagonists are widely used for the relief of urinary retention secondary to benign prostatic hyperplasia (BPH). While the five Food and Drug Administration-approved α 1-AR antagonists (terazosin, doxazosin, alfuzosin, tamsulosin, and silodosin) share similar efficacy, they differ in tolerability, with reports of ejaculatory dysfunction. The aim of the present work was to rev…
New Search Next